Page 2 - Laurus Labs

Laurus gains 15% in 2 days on robust CDMO outlook; updates on AIDS drug biz

The broader outlook for the CDMO industry with small molecules is positive, and the management of Laurus Labs remains committed to its 2025 growth outlook

Laurus Labs plunges 15% as analysts warn of overvaluation; buy, sell, hold?

Laurus Labs share slipped 15 per cent at Rs 510.60 a piece on the BSE in Monday's intraday trade

I-T Dept imposes Rs 3.86 cr penalty on Laurus Labs for disallowed deduction

Laurus Labs further clarified that the penalty proceedings would not have any financial impact on the company

Laurus Labs hits 2-yr high on hopes of healthy earnings; up 44% in 3 months

The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.

Laurus Labs up 7% on stable sales, better margin guidance for H2 FY25

The company said expectations of a better second half of the current financial year (H2FY25) is based on facility ramp up, delivery of late-phase NCE projects, and Ebitda margins improvement

Aster DM, Laurus Labs among 5 smallcap stock ideas in a falling market

Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.

Pharma stocks soar 6% as investors respond to double dose of Good News!

Individually, shares of Laurus Labs rose up to 5.55 per cent at Rs 517.90 per share, Akums Drugs and Pharmaceuticals shares locked in 5 per cent upper circuit at Rs 910.55 a piece

F&O stocks in focus: Long buildup seen in Naukri, Voltas, Laurus Labs

Stocks with long buildup in August series: Key levels to track on Voltas, Naukri and Laurus Labs as these stocks could potentially gain up to 9 per cent from present levels.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Goldman Sachs bullish on Indian CDMO sector, recommends buying these stocks

Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia

Slow improvement in sales could weigh on pharma firm Laurus' performance

Company reported lower-than-expected revenue after missing target in key segment

Fresh capacity, investments may drive gains for Laurus Labs by FY25

Despite these cuts, the brokerage maintains a buy rating on the stock

Laurus Labs slips 4% as arm gets 5 observations post USFDA inspection

Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.

Stocks to Watch: Wipro, Laurus Labs, Axis Bank, SRF, KIOCL, CGDs, BoB

Stocks to Watch on December 13, 2023: PE giant Bain Capital is likely to sell up to 1.1 per cent stake in Axis Bank via a block deal, reported Moneycontrol

US regulators inspect Dr Reddy's, other Indian pharma majors: Report

Rivals Sun Pharma's Dadra facility and Torrent Pharmaceuticals Ltd's oncology unit are also undergoing FDA inspections

Pharma company Laurus Labs acquires 87.59% stake in Laurus Bio Private

The acquisition was made through a secondary purchase from the promoter group shareholders of Laurus Bio on November 20, 2023

Over 75% pharma stocks eye breakout; most may see up to 15% upside

Barring, Pfizer, Gland Pharma, and Laurus Labs, all other constituents of Nifty Pharm Index trade over the 200-day simple moving average (SMA),

Laurus Labs Q1FY24 results: PAT sees massive drop of 90% YoY at Rs 25 cr

Lower sales, operational deleverage and elevated expenses were listed as reasons for subdued financial performance

Laurus Labs slips 5%, hits over 2-year low post December quarter results

Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment